PHARMING'S ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD IN LEIDEN ON 16 APRIL 2008

Leiden, The Netherlands, March 4, 2008. Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) announced today that the Company's Annual General Meeting of Shareholders (AGM) will be held at the Pharming headquarters in Leiden, the Netherlands on 16 April 2008 commencing at 15.00 pm CET.

Pharming intends to publish a notice in the *Financieele Dagblad* and the Euronext Daily Official List (*Officiële Prijscourant*) of 1 April 2008. All documentation relating to the AGM will be available on Pharming's website as of that date.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for Hereditary Angioedema and human lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with Novathera) and DNA repair (via DNage). Additional information is available on the Pharming website, http://www.pharming.com and on http://www.dnage.nl.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.

Contact:

Carina Hamaker (NL) Investor Voice T: +31 (0)6 537 499 59 Rein Strijker Pharming Group NV T: +31 (0)7 5247 400